Genetically modified immunocompetent cells in HIV infection

Gene Ther. 2001 Nov;8(21):1593-600. doi: 10.1038/sj.gt.3301569.

Abstract

Even in the era of highly active antiretroviral therapy (HAART), gene therapy (GT) can remain a promising approach for suppressing HIV infection, especially if complemented with other forms of pharmacological and immunological intervention. A large number of vectors and targets have been studied. Here we discuss the potential of genetically treated, antigen-specific immunocompetent cells for adoptive autologous immunotherapy of HIV infection. Cellular therapies with gene-modified CD8 and CD4 lymphocytes are aimed at reconstituting the antigen-specific repertoires that may be deranged as a consequence of HIV infection. Even if complete eradication of HIV from the reservoirs cannot be achieved, reconstitution of cellular immunity specific for opportunistic pathogens and for HIV itself is a desirable option to control progression of HIV infection and AIDS pathogenesis better.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS-Related Opportunistic Infections / immunology
  • Adoptive Transfer / methods*
  • Antigen-Presenting Cells / immunology
  • Antigens, CD34
  • Antiretroviral Therapy, Highly Active
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / transplantation*
  • CD8-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / transplantation*
  • Combined Modality Therapy
  • Cryopreservation
  • Epitopes
  • Genes, tat
  • Genetic Therapy / methods*
  • HIV / genetics
  • HIV Infections / immunology
  • HIV Infections / therapy*
  • Humans
  • Tissue Preservation

Substances

  • Antigens, CD34
  • Epitopes